bevacizumab-adcd 400 MG in 16 ML Injection

RxCUI: 2627658
RxNorm name: bevacizumab-adcd 400 MG in 16 ML Injection
Display name: bevacizumab-adcd 400 MG in 16 ML Injection
Full name: bevacizumab-adcd 400 MG in 16 ML Injection
Term type: PSN
Status: DailyMed mapping
Updated: 2026-06-04 23:38:57

Purple Book Biologic Products#

BLA, Proprietary name, Proper name table
BLA	Proprietary name	Proper name	License type	Status	Latest source
761268	Vegzelma	bevacizumab-adcd	351(k) Biosimilar	Rx	2026-06-01

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Vegzelma	BEVACIZUMAB-ADCD	CELLTRION USA, Inc.	4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe	2025-05-08	Warnings, Adverse reactions	Exact identifier rxcui: 2627658

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set ID	RxNorm string	TTY	SPL version	Label	Effective
4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe	bevacizumab-adcd 400 MG in 16 ML Injection	PSN	4	These highlights do not include all the information needed to use VEGZELMA safely and effectively. See full prescribing information for VEGZELMA. VEGZELMA (bevacizumab-adcd) injection, for intravenous use Initial U.S. Approval: 2022 VEGZELMA (bevacizumab-adcd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences b	20250508
4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe	16 ML bevacizumab-adcd 25 MG/ML Injection	SCD	4	These highlights do not include all the information needed to use VEGZELMA safely and effectively. See full prescribing information for VEGZELMA. VEGZELMA (bevacizumab-adcd) injection, for intravenous use Initial U.S. Approval: 2022 VEGZELMA (bevacizumab-adcd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences b	20250508
4cdcccda-7b9a-49d0-ac50-f4605a3c0ebe	bevacizumab-adcd 400 MG per 16 ML Injection	SY	4	These highlights do not include all the information needed to use VEGZELMA safely and effectively. See full prescribing information for VEGZELMA. VEGZELMA (bevacizumab-adcd) injection, for intravenous use Initial U.S. Approval: 2022 VEGZELMA (bevacizumab-adcd) is biosimilar Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences b	20250508